Market revenue in 2023 | USD 4.0 million |
Market revenue in 2030 | USD 6.2 million |
Growth rate | 6.5% (CAGR from 2023 to 2030) |
Largest segment | Bioavailability & bioequivalence studies |
Fastest growing segment | Bioavailability & Bioequivalence Studies |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test type |
Key market players worldwide | IQVIA Holdings Inc, Labcorp Holdings Inc, Thermo Fisher Scientific Inc, Pharmaron Beijing Co Ltd Ordinary Shares - Class H, Charles River Laboratories International Inc, Syneos Health, Intertek Group PLC |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell & gene therapy bioanalytical testing services market will help companies and investors design strategic landscapes.
Bioavailability & bioequivalence studies was the largest segment with a revenue share of 35% in 2023. Horizon Databook has segmented the Norway cell & gene therapy bioanalytical testing services market based on bioavailability & bioequivalence studies, pharmacokinetics, pharmacodynamics, other test type covering the revenue growth of each sub-segment from 2018 to 2030.
Norway has been becoming a major leader in biotechnology, especially in the fields of gene and cell therapy. The country has been making investments in life sciences and biotechnology research, with an emphasis on creating innovative treatments including gene & cell therapies.
Strong healthcare systems, academic institutions, and a pro-regulatory attitude make the country a desirable place for biotechnology companies & research initiatives. Moreover, bioanalytical testing in Norway encompasses a wide range of analyses conducted on biological samples such as blood, urine, tissue, and other bodily fluids for various purposes including clinical diagnostics, pharmaceutical development, environmental monitoring, & food safety.
Norway has advanced facilities and expertise in bioanalytical sciences, contributing to research, healthcare, and industry both domestically & internationally.
Horizon Databook provides a detailed overview of country-level data and insights on the Norway cell & gene therapy bioanalytical testing services market , including forecasts for subscribers. This country databook contains high-level insights into Norway cell & gene therapy bioanalytical testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account